Premium
DISCOVERY OF A NOVEL, POTENTIAL FIRST‐IN‐CLASS MALT1 PROTEASE INHIBITOR FOR THE TREATMENT OF B CELL LYMPHOMAS
Author(s) -
Philippar U.,
Lu T.,
Vloemans N.,
Bekkers M.,
Nuffel L.,
Gaudiano M.,
WnukLipinska K.,
Van Der Leede B.,
Amssoms K.,
Kimpe K.,
Medaer B.,
Greway T.,
Abraham Y.,
Cummings M.,
Trella E.,
Vanhoof G.,
Sun W.,
Thuring J.,
Connolly P.,
Linders J.,
Gerecitano J.,
Goldberg J.,
Edwards J.P.,
Elsayed Y.,
Smit J.,
Bussolari J.,
Attar R.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.88_2629
Subject(s) - cancer research , ibrutinib , bruton's tyrosine kinase , b cell , diffuse large b cell lymphoma , biology , bcl10 , signal transduction , microbiology and biotechnology , chemistry , lymphoma , tyrosine kinase , immunology , chronic lymphocytic leukemia , leukemia , antibody